Judith Ng-Cashin

55 year

Health Technology

Consumer Services

Profile

Judith Ng-Cashin served as the Chief Medical Officer at AOBiome Therapeutics, Inc. She also served as the Chief Medical Officer and Executive Vice President at Eagle Pharmaceuticals, Inc. Prior to her professional roles, she earned an undergraduate degree from Duke University and a doctorate from Rush Medical College.

Former positions of Judith Ng-Cashin

Companies	Position	End
EAGLE PHARMACEUTICALS, INC.	Chief Tech/Sci/R&D Officer	2021-12-26
AOBiome Therapeutics, Inc. AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.	Chief Tech/Sci/R&D Officer	-

See the detail of Judith Ng-Cashin's experience

Training of Judith Ng-Cashin

Duke University	Undergraduate Degree
Rush Medical College	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Judith Ng-Cashin's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
EAGLE PHARMACEUTICALS, INC.	Health Technology

Private companies	1
AOBiome Therapeutics, Inc. AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.	Health Technology